Search results for "Proportion"

showing 10 items of 877 documents

Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: The need for a multi…

2006

To investigate the influence on local control after fractionated radiotherapy of hypoxia measured in unirradiated tumours using the hypoxic marker Pimonidazole, using multivariate approaches.Five human squamous cell carcinoma lines (FaDu, UT-SCC-15, UT-SCC-14, XF354, and UT-SCC-5) were transplanted subcutaneously into the right hind-leg of NMRI nude mice. Histological material was collected from 60 unirradiated tumours after injection of Pimonidazole. The relative hypoxic area within the viable tumour area (Pimonidazole hypoxic fraction, pHF) was determined in seven serial 10 microm cross-sections per tumour by fluorescence microscopy and computerized image analysis. Local tumour control wa…

MaleMultivariate statisticsPathologymedicine.medical_specialtyMice NudeMiceImaging Three-DimensionalCell Line TumorLabellingBiomarkers TumorCarcinomamedicineAnimalsHumansPimonidazoleRadiology Nuclear Medicine and imagingProportional hazards modelbusiness.industryDose fractionationHematologyHypoxia (medical)Prognosismedicine.diseaseXenograft Model Antitumor AssaysCell HypoxiaTreatment OutcomeOncologyNitroimidazolesCarcinoma Squamous CellBiomarker (medicine)FemaleDose Fractionation Radiationmedicine.symptombusinessRadiotherapy and Oncology
researchProduct

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

2015

BACKGROUND: Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with concomitant cardiovascular diseases, than in most other populations. We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascular outcomes in patients with type 2 diabetes who had had a recent acute coronary event.METHODS: We randomly assigned patients with type 2 diabetes who had had a myocardial infarction or who had been hospitalized for unstable angina within the previous 180 days to receive lixisenatide or placebo in addition to locally determined standards of care. The trial was designed with adequate statistical power to …

MaleMyocardial InfarctionKaplan-Meier Estimate2700 General MedicineType 2 diabetesAnginachemistry.chemical_compoundTreatment FailureMyocardial infarctionResearch Support Non-U.S. Gov'tHemoglobin AGeneral MedicineAnginaMiddle AgedMulticenter StudyCardiovascular DiseasesRandomized Controlled TrialCardiologyFemalelixisenatideType 2medicine.medical_specialtyAcute coronary syndromeGlycosylated610 Medicine & healthUnstableGlucagon-Like Peptide-1 Receptor11171 Cardiocentro TicinoLixisenatideAcute Coronary Syndrome; Aged; Angina Unstable; Cardiovascular Diseases; Diabetes Mellitus Type 2; Female; Glucagon-Like Peptide-1 Receptor; Hemoglobin A Glycosylated; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peptides; Proportional Hazards Models; Treatment FailureInternal medicineJournal ArticleDiabetes MellitusmedicineHumansHypoglycemic AgentsAngina UnstableAcute Coronary SyndromeAgedProportional Hazards ModelsHemoglobin A GlycosylatedUnstable anginabusiness.industrySemaglutideta3121medicine.diseaseDiabetes Mellitus Type 2chemistryMyocardial infarction complicationsPeptidesbusinessNew England Journal of Medicine
researchProduct

Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk…

2018

AIMS: Carotid intima media thickness (CIMT) predicts cardiovascular (CVD) events, but the predictive value of CIMT change is debated. We assessed the relation between CIMT change and events in individuals at high cardiovascular risk. METHODS AND RESULTS: From 31 cohorts with two CIMT scans (total n = 89070) on average 3.6 years apart and clinical follow-up, subcohorts were drawn: (A) individuals with at least 3 cardiovascular risk factors without previous CVD events, (B) individuals with carotid plaques without previous CVD events, and (C) individuals with previous CVD events. Cox regression models were fit to estimate the hazard ratio (HR) of the combined endpoint (myocardial infarction, s…

MaleMyocardial Infarctionlcsh:MedicinePROGRESSIONCardiovascular Medicine030204 cardiovascular system & hematologyVascular MedicineBiochemistryCarotid Intima-Media ThicknessGeographical locationsDISEASE0302 clinical medicineRisk FactorsGermanyMedicine and Health SciencesMedicineCardiac and Cardiovascular SystemsMyocardial infarctionskin and connective tissue diseaseslcsh:ScienceARTERY INTIMAStrokeIntersectoral CollaborationPOPULATIONCardiovascular Diseases/diagnosisMETABOLIC SYNDROMEeducation.field_of_studyKardiologiMultidisciplinaryAgricultural and Biological Sciences(all)VDP::Medical disciplines: 700::Clinical medical disciplines: 750QHazard ratioVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750RMiddle AgedPrognosisPredictive value3. Good healthStrokeEuropeNeurologyItalyCardiovascular DiseasesHYPERTENSIVE MENCardiologycardiovascular systemMedicineFemaleResearch Articlemedicine.medical_specialtyHigh cardiovascular risk.Cerebrovascular DiseasesSciencePopulationCardiology030209 endocrinology & metabolismATHEROSCLEROSIS RISKArbetsmedicin och miljömedicin03 medical and health sciencesCarotid intima media thickness (CIMT)Internal medicineHumansEuropean Unionddc:610cardiovascular diseaseseducationAgedSwedenBiochemistry Genetics and Molecular Biology(all)Proportional hazards modelbusiness.industrylcsh:RHealth Risk AnalysisCorrectionOccupational Health and Environmental HealthAtherosclerosismedicine.diseaseConfidence intervalHealth CareIntima-media thicknessMYOCARDIAL-INFARCTIONMedical Biophysicslcsh:QVASCULAR RISKsense organsCarotid intima media thickness Cardiovascular riskPeople and placesMetabolic syndromebusinessFOLLOW-UP030217 neurology & neurosurgeryGenetics and Molecular Biology(all)
researchProduct

The Molecular Genetic Architecture of Self-Employment

2013

Economic variables such as income, education, and occupation are known to affect mortality and morbidity, such as cardiovascular disease, and have also been shown to be partly heritable. However, very little is known about which genes influence economic variables, although these genes may have both a direct and an indirect effect on health. We report results from the first large-scale collaboration that studies the molecular genetic architecture of an economic variable-entrepreneurship-that was operationalized using self-employment, a widely-available proxy. Our results suggest that common SNPs when considered jointly explain about half of the narrow-sense heritability of self-employment es…

MaleNetherlands Twin Register (NTR)Multifactorial InheritanceHeredityEpidemiologyEconomicsIntelligenceTwinsGenome-wide association studyCORONARY HEART-DISEASESocial and Behavioral SciencesTheoreticalMissing heritability problemModelsMISSING HERITABILITYMicroeconomicsTwins DizygoticSOCIOECONOMIC-STATUSRegistriesGenetics0303 health sciencesMultidisciplinaryStatistics05 social sciencesQRGenomicsSingle NucleotideOccupational and Industrial Health/dk/atira/pure/sustainabledevelopmentgoals/decent_work_and_economic_growth3. Good healthCARDIOVASCULAR-DISEASEGenetic EpidemiologyMeta-analysisScience & Technology - Other TopicsMedicineFemalePublic HealthBehavioral and Social Aspects of HealthResearch ArticlePersonalityEmploymentGenotypeClinical Research DesignGeneral Science & Technology515 PsychologyScienceeducationSingle-nucleotide polymorphismBiostatisticsBiologyPolymorphism Single NucleotideMonozygotic03 medical and health sciencesGenome Analysis Tools0502 economics and businessMD MultidisciplinaryGenome-Wide Association StudiesGenetics/dk/atira/pure/keywords/cohort_studies/netherlands_twin_register_ntr_DizygoticHumansStatistical MethodsHuman heightPolymorphismGENOME-WIDE ASSOCIATIONBiology030304 developmental biologyGenetic associationEDUCATIONAL-ATTAINMENTScience & TechnologyComplex TraitsMULTIDISCIPLINARY SCIENCESComputational BiologyHuman GeneticsSDG 8 - Decent Work and Economic GrowthTwins Monozygoticta3121HeritabilityModels TheoreticalGenetic architectureCOMMON SNPS EXPLAINLARGE PROPORTIONGenetic PolymorphismRISK-FACTORSGene-Environment Interaction3111 BiomedicineMeta-AnalysesHUMAN HEIGHTPopulation GeneticsMathematics050203 business & managementGenome-Wide Association Study
researchProduct

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

2001

Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, whi…

MaleOncologyCancer ResearchPathologyMultivariate analysisDatabases FactualSettore MED/06 - Oncologia MedicaColorectal cancerGene mutationmedicine.disease_cause0302 clinical medicineGenotypeColorectal cancer Ki-ras mutationRegistriesAged 80 and over0303 health sciencesMutationValineMiddle Aged3. Good healthKRAS Mutation Analysismedicine.anatomical_structureOncologyPresented by the Kirsten ras in-colorectal-cancer collaborative group030220 oncology & carcinogenesisFemaleColorectal NeoplasmsAdultmedicine.medical_specialtyAdolescentGenotypeoverall survivalMutation MissenseRectumcolorectal cancerDisease-Free Survival03 medical and health sciencesInternal medicinemedicineHumansPoint MutationK-rasCodoncolorectal cancer; K-ras; prognosis; overall survivalAgedNeoplasm StagingProportional Hazards Models030304 developmental biologybusiness.industryCancermedicine.diseaseSurvival AnalysisGenes rasMultivariate Analysisprognosisbusiness
researchProduct

The prognostic value of biological markers in paediatric Hodgkin lymphoma

2015

Abstract Background Many biological and inflammatory markers have been proposed as having a prognostic value at diagnosis of Hodgkin lymphoma (HL), but very few have been validated in paediatric patients. We explored the significance of these markers in a large population of 769 affected children. Patients and methods By using the database of patients enrolled in A.I.E.O.P. (Associazione Italiana di Emato-Oncologia Pediatrica) trial LH2004 for paediatric HL, we identified 769 consecutive patients treated with curative intent from 1st June 2004 to 1st April 2014 with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), or hybrid COPP/ABV (cyclophosphamide, vincristine, prednisone, pr…

MaleOncologyCancer ResearchPathologyTime FactorsDatabases Factualmedicine.medical_treatmenthodgkin lymphoma; paediatric; prognostic factorHodgkin lymphoma; Paediatric; Prognostic factor; Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers Tumor; Child; Child Preschool; Databases Factual; Disease Progression; Disease-Free Survival; Female; Ferritins; Hodgkin Disease; Humans; Infant; Infant Newborn; Italy; Kaplan-Meier Estimate; Leukocyte Count; Male; Multivariate Analysis; Neoplasm Staging; Platelet Count; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Blood Platelets; EosinophilsKaplan-Meier EstimateProcarbazineLeukocyte Countchemistry.chemical_compound0302 clinical medicineRisk FactorsPrednisoneAntineoplastic Combined Chemotherapy ProtocolsChildPrognostic factorTumorAge FactorsHodgkin DiseaseVinblastineTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyOncologyPaediatricChild Preschool030220 oncology & carcinogenesisDisease ProgressionFemalemedicine.drugBlood Plateletsmedicine.medical_specialtyVincristineAdolescentDacarbazineBleomycinDisease-Free SurvivalDatabases03 medical and health sciencesPredictive Value of TestsInternal medicineBiomarkers TumormedicineHumansPreschoolFactualNeoplasm StagingProportional Hazards ModelsRetrospective StudiesChemotherapyPlatelet Countbusiness.industryInfant NewbornInfantNewbornEosinophilschemistryABVDFerritinsMultivariate AnalysisbusinessBiomarkersHodgkin lymphoma030215 immunologyEuropean Journal of Cancer
researchProduct

A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer

2008

In the light of findings indicating that cannabinoids can affect the proliferation of a number of cancer cell types and that cannabinoid receptor expression is higher in prostate cancer cell lines than in non-malignant cells, we investigated whether the level of cannabinoid 1 receptor immunoreactivity (CB(1)IR) in prostate cancer tissues is associated with disease severity and outcome. Formalin-fixed paraffin-embedded non-malignant and tumour tissue samples from patients who were diagnosed with prostate cancer at a transurethral resection for voiding problems were used. CB(1)IR, which was scored in a total of 399 cases, was associated with the epithelial cell membranes, with little staining…

MaleOncologyCancer Researchmedicine.medical_specialtyPathologyPrognostic variableCannabinoid receptormedicine.medical_treatmentAdenocarcinomaProstate cancerReceptor Cannabinoid CB1Internal medicineBiomarkers TumormedicineHumansSurvival rateAgedCell ProliferationProportional Hazards Modelsbusiness.industryProportional hazards modelCell MembraneProstatic NeoplasmsEpithelial Cellsmedicine.diseaseImmunohistochemistrySurvival RateOncologyArea Under CurveCancer cellImmunohistochemistryCannabinoidbusinessEuropean Journal of Cancer
researchProduct

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-sm…

2015

Background: This trial was designed to evaluate the activity and safety of ganetespib in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) and to identify patient populations most likely to benefit from the combination. Patients and methods: Patients with one prior systemic therapy for advanced disease were eligible. Docetaxel (75 mg/m<sup>2</sup> on day 1) was administered alone or with ganetespib (150 mg/m<sup>2</sup> on days 1 and 15) every 3 weeks. The primary end points were progression-free survival (PFS) in two subgroups of the adenocarcinoma population: patients with elevated lactate dehydrogenase (eLDH) and mutated KRAS (mKRAS). Resul…

MaleOncologyHSP90 inhibitormedicine.medical_specialtyLung NeoplasmsPopulationGanetespibPhases of clinical researchDocetaxelAdenocarcinomaNeutropeniaDisease-Free SurvivalProto-Oncogene Proteins p21(ras)Carcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHSP90 Heat-Shock ProteinsLung cancereducationAgedProportional Hazards Modelseducation.field_of_studyL-Lactate Dehydrogenasebusiness.industryHazard ratioHematologyMiddle AgedTriazolesmedicine.diseaseTreatment OutcomeAdvanced NSCLCOncologyDocetaxelGanetespibAdenocarcinomaFemaleTaxoidsbusinessmedicine.drugAnnals of Oncology
researchProduct

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.

2022

Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC). However, biomarkers that predict treatment success and survival remain an unmet need.Patients with HCC put on PD-(L)1-based immunotherapy were included in a training set (n = 190; 6 European centers) and a validation set (n = 102; 8 European centers). We investigated the prognostic value of baseline variables on overall survival using a Cox model in the training set and developed the easily applicable CRAFITY (CRP and AFP in ImmunoTherapY) score. The score was validated in the independent, external cohort, and evaluated in a cohort of patie…

MaleOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularBevacizumabAntineoplastic Agents610 Medicine & healthAntibodies Monoclonal HumanizedAntineoplastic Agents ImmunologicalAtezolizumabGermanyInternal medicinemedicineHumans610 Medicine & healthAgedProportional Hazards ModelsRetrospective StudiesHepatologyProportional hazards modelbusiness.industryLiver NeoplasmsMiddle AgedSorafenibPrognosismedicine.diseaseBevacizumabRegimenTreatment OutcomeItalyHepatocellular carcinomaCohortFemaleImmunotherapyLiver cancerbusinessSwitzerlandmedicine.drug
researchProduct

Coagulation and inflammation in long‐term cancer survivors: results from the adult population

2018

Essentials The increase of cancer survival remains curtailed by cardiovascular mortality. We studied a large range of inflammatory and coagulation biomarkers in long-term cancer survivors. Cancer history has an important impact on mortality independent of cardiovascular risk factors. Fibrinogen and von Willebrand factor are potential biomarkers in survivors of increased mortality. Summary Background The advances in cancer treatment and detection of early cancer have resulted in a steady increase in the number of of cancer survivors over the years. However, because of the long-term toxic effects of chemotherapy and radiotherapy, the incidence of cardiovascular disease (CVD) is increasing in …

MaleOncologyTime Factorsmedicine.medical_treatmentDiseasecoagulation factors030204 cardiovascular system & hematologyFibrinogen0302 clinical medicineCancer Survivorscardiovascular diseaseRisk FactorsGermanyProspective StudiesRISKIncidence (epidemiology)survivorsHematologyMiddle AgedPrognosisCARDIOVASCULAR-DISEASECardiovascular Diseases030220 oncology & carcinogenesisCohortFemaleHEALTHInflammation Mediatorsmedicine.drugAdultmedicine.medical_specialtyVON-WILLEBRAND-FACTORRisk AssessmentOVARIAN-CANCER03 medical and health sciencesInternal medicinevon Willebrand FactormedicinecancerHumansCOHORTBlood CoagulationMETAANALYSISAgedInflammationProportional hazards modelbusiness.industryMORTALITYFibrinogenCancermedicine.diseaseRadiation therapyATHEROSCLEROSISPLASMA-FIBRINOGENOvarian cancerbusinessBiomarkersJournal of Thrombosis and Haemostasis
researchProduct